BI 1015550: A Study Drug to Improve Lung Function for People with Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a disease that causes the lungs to become scarred and breathing difficult. BI 1015550 is a study drug to help people with IPF. Research is needed to know the safety, effectiveness, and side effects BI 1015550. The information we gain may aid future patients.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
- Ages 18-40 years old
- IPF diagnosis
- On stable treatment with nintedanib or pirfenidone for at least 12 weeks, or not on treatment with either nintedanib or pirfenidone for at least 8 weeks before starting the study
- Acute IPF exacerbation (your disease declines suddenly and quickly) within 3 months prior to and/or during the screening period
- Human immunodeficiency virus (HIV) and viral hepatitis
- Confirmed infection with SARS-CoV-2 (COVID-19) and not fully recovered within 4 weeks before starting the study
- Major surgery within 6 weeks prior to or planned during the study, e.g. hip replacement.
- Women who are pregnant, nursing, or who plan to become pregnant while in the study
Will I be paid for my time?